Program Schedule

Friday, November 9
6:30 am – 6 pm Registration Open
8:00 am – 8:10 am President’s Welcome and Meeting Overview
William E. Murphy MD
Hoag Cancer Center
President, SBT
8:10 am – 8:15am Welcome
J. Carl Barrett, PhD
Center for Cancer Research
National Cancer Institute
8:15 am – 9:05 am Keynote Address:
Hallmarks of Progress in Human Cancer Immunotherapy

Steven A. Rosenberg, MD, PhD
Center for Cancer Research
National Cancer Institute
9:05 am – 12:25 pm Joint Session – Cytokines
Jon M. Wigginton, MD
Center for Cancer Research
National Cancer Institute

Paul Sondel, MD, PhD
University of Wisconsin,
Comprehensive Cancer Center

9:05 am – 9:30 am Interleukin18: A Potent Immunomodulatory Dendrikine with Antitumor Activity
Michael Lotze, MD
University of Pittsburgh Medical Center
9:30 am – 9:55 am IL-15: Relevance in Biology and Disease
Michael Caligiuri, MD
Ohio State University School of Medicine
9:55 am – 10:20 am The Laboratory and Clinical Biology of Cancer Treatment with Tumor Reactive mAb Linked to IL2
Paul Sondel, MD, PhD
University of Wisconsin
10:20 am – 10:40 am Break
10:40 am – 11:05 am Preclinical and Clinical Investigation of IL-12/Pulse IL-2
Jon M. Wigginton, MD
National Cancer Institute – Center for Cancer Research
11:05 am – 11:30 am Phase I Trial of Twice-Weekly IV rhIL- 12 Plus Low-Dose SC IL-2 in Patients with Melanoma and Renal Cell Cancer
Jared Gollob, MD
Beth Israel Deaconess Medical Center
11:30 am – 11:55 am IL-7: Emerging Role In Immunorestoration and Vaccination
Terry Fry, MD
Center for Cancer Research
National Cancer Institute
11:55 am – 12:10 pm Tumor Vaccination with Interleukin-12 and Granulocyte Macrophage-Colony Stimulating Factor-Encapsulated Microspheres: Co-induction of Innate and Adaptive Immunity Promotes Cure of Disseminated Disease
Nejat K. Egilmez, PhD
State University of New York at Buffalo
12:10 pm – 12:25 pm A Randomized Phase III Trial of High- Dose Interleukin-2
David F. McDermott, MD
Beth Israel Deaconess Medical Center
12:25 pm – 2:15 pm Box Lunch/Poster Session (authors must be present)


Concurrent Session 1 Concurrent Session 2
2:15 pm – 5:00 pm Angiogenesis
Co-Chairs: Steven K. Libutti, MD
National Cancer InstituteMichael O’ Reilly, MD
University of Texas, M.D. Anderson Cancer Center
Vaccine/Dendritic Cells
Co-Chairs: Mary L. (Nora) Disis, MD
University of WashingtonWalter Storkus, PhD
University of Pittsburgh School of Medicine
2:15 pm – 2:40 pm Phenotypic Diversity of Endothelial Cells is Defined by the Organ Microenvironment
Cheryl Baker, PhD
University of Texas, M.D. Anderson Cancer Center
Preclinical Strategies to Improve Dendritic Cell-Based Tumor Vaccines
James Mulé, PhD
University of Michigan Medical Center
2:40 pm – 3:05 pm The Imaging of Angiogenesis
Peter Choyke, MD
Clinical Center,
National Institutes of Health
Dendritic Cells as Vectors and Targets for Therapy
Karolina Palucka, MD, PhD
Baylor Institute for Immunology Research
3:05 pm – 3:30 pm Molecular Determinants of the Angiogenic Switch and Tumor Progression
Marsha Moses, PhD
Harvard Medical School, Childrens Hospital
Th1 and Th2 CD4+ T Cell Responses in Melanoma and Renal Cell Carcinoma
Walter Storkus, PhD
University of Pittsburgh School of Medicine
3:30 pm – 3:50 pm
3:50 pm – 4:15 pm Angiogenesis and Gene Expression Profiling
Steven K. Libutti, MD
Center for Cancer Research
National Cancer Institute
Multi-Epitope Peptide Vaccines with GMCSF and IL2: CTL Responses in the Periphoral Blood and in the Sentinel Immunized Node
Craig L. Slingluff, Jr., MD
University of Virginia Health Science Center
4:15 pm – 4:30 pm In Vivo Tumor Imaging Using Near Infrared Labeled Endostatin
Kevin Camphausen, MD
Center for Cancer Research
National Cancer Institute
Immunization of HLA-A2+ Melanoma Patients in the Adjuvant Setting with a Mutated gp100 Peptide (209-2M) Induces Specific T Cell Immune Responses
John W. Smith, II, MD
Providence Cancer Center, Earle A. Chiles
Research Institute
4:30 pm – 4:45 pm Peptide-Targeting IL-12 to avb3 Integrin Mediates Potent Antiangiogenic Activity
Erin Dickerson, PhD
University of Wisconsin, School of Veterinary Medicine
Transduction of Human Dendritic Cells with a Melanoma Polyepitope Simultaneously Primes Multiple T-cell Responses but Ultimately Results in Immunodominance
Andrew Jackson, PhD
St. James Hospital, Imperial Cancer Research Fund
4:45 pm – 5:00 pm Signal and Transcriptional Activation of Proinflammatory and Proangiogenic Factor Expression by Cancer Cells as a Target for Biological Therapy
Carter Van Waes, MD, PhD
Tumor Biology Section, HNSB, NIDCD
Comparative Analysis of Necrotic and Apoptotic Tumor Cells as a Source of Antigen(s) in Dendritic Cell-Based Immunization
Yoshihito Kotera, MD
University of Michigan Medical Center
5:00 pm – 6:30 pm
Cocktail Reception
Hyatt Regency Bethesda